Defactinib companion diagnostic - Verastem/LabCorp

Drug Profile

Defactinib companion diagnostic - Verastem/LabCorp

Alternative Names: Defactinib companion diagnostic; VS-6063 companion diagnostic

Latest Information Update: 17 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratory Corporation of America Holdings; Verastem
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Mesothelioma

Most Recent Events

  • 10 Jan 2013 Verastem and Laboratory Corporation of America Holding are collaborating to develop a companion diagnostic for defactinib
  • 09 Jan 2013 Clinical trials in Mesothelioma (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top